| Year |
Citation |
Score |
| 2020 |
Zhou Y, Lian H, Shen N, Korm S, Lam AKP, Layton O, Huiting LN, Li D, Miao K, Zeng A, Landesman-Bollag E, Seldin DC, Fu H, Hong L, Feng H. The multifaceted role of protein kinase CK2 in high-risk acute lymphoblastic leukemia. Haematologica. PMID 32817283 DOI: 10.3324/Haematol.2020.246918 |
0.729 |
|
| 2016 |
Lian H, Li D, Zhou Y, Landesman-Bollag E, Zhang G, Anderson NM, Tang KC, Roderick JE, Kelliher MA, Seldin DC, Fu H, Feng H. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells. Haematologica. PMID 27758824 DOI: 10.3324/Haematol.2016.154013 |
0.718 |
|
| 2016 |
Lee SY, Meehan RS, Seldin DC, Sloan JM, Quillen K, Shelton A, Brauneis D, Sanchorawala V. Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplantation. PMID 27183092 DOI: 10.1038/Bmt.2016.132 |
0.322 |
|
| 2016 |
Stanford EA, Wang Z, Novikov O, Mulas F, Landesman-Bollag E, Monti S, Smith BW, Seldin DC, Murphy GJ, Sherr DH. The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. Bmc Biology. 14: 20. PMID 26984638 DOI: 10.1186/S12915-016-0240-Y |
0.731 |
|
| 2016 |
Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26858336 DOI: 10.1200/Jco.2015.63.6530 |
0.31 |
|
| 2015 |
Sissoko M, Sanchorawala V, Seldin D, Sworder B, Angelino K, Broce M, Berk J, Sloan JM. Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 1-7. PMID 26488936 DOI: 10.3109/13506129.2015.1092433 |
0.33 |
|
| 2015 |
Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20 year experience. Blood. PMID 26443620 DOI: 10.1182/Blood-2015-08-662726 |
0.329 |
|
| 2015 |
Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. Embo Molecular Medicine. 7: 688. PMID 25940533 DOI: 10.15252/Emmm.201505318 |
0.489 |
|
| 2015 |
Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 1445-51. PMID 25858810 DOI: 10.1016/J.Bbmt.2015.04.001 |
0.309 |
|
| 2015 |
Liedtke M, Merlini G, Landau HJ, Comenzo R, Seldin DC, Weiss BM, Zonder JA, Walling J, Kinney G, Koller M, Gertz MA. The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. Journal of Clinical Oncology. 33: 8614-8614. DOI: 10.1200/Jco.2015.33.15_Suppl.8614 |
0.336 |
|
| 2015 |
Gertz MA, Landau HJ, Comenzo R, Seldin DC, Weiss BM, Zonder JA, Walling J, Kinney G, Koller M, Liedtke M. Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction. Journal of Clinical Oncology. 33: 8514-8514. DOI: 10.1200/Jco.2015.33.15_Suppl.8514 |
0.312 |
|
| 2015 |
Prokaeva T, Spencer B, Sun F, McConnell N, O'hara RM, Seldin DC, Connors L, Sanchorawala V. Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio Blood. 126: 2956-2956. DOI: 10.1182/Blood.V126.23.2956.2956 |
0.319 |
|
| 2014 |
Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. Embo Molecular Medicine. 6: 1493-507. PMID 25319546 DOI: 10.15252/emmm.201404190 |
0.414 |
|
| 2014 |
Lee SY, Sanchorawala V, Seldin DC, Mark Sloan J, Andrea N, Quillen K. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 21: 149-53. PMID 24779777 DOI: 10.3109/13506129.2014.900486 |
0.326 |
|
| 2014 |
Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Review of Hematology. 7: 143-56. PMID 24350907 DOI: 10.1586/17474086.2014.858594 |
0.301 |
|
| 2014 |
Gray Gilstrap L, Niehaus E, Malhotra R, Ton VK, Watts J, Seldin DC, Madsen JC, Semigran MJ. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 33: 149-56. PMID 24200511 DOI: 10.1016/J.Healun.2013.09.004 |
0.308 |
|
| 2014 |
Meehan R, Seldin D, Sloan JM, Quillen K, Brauneis D, Shelton AC, Sanchorawala V. Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients Blood. 124: 5499-5499. DOI: 10.1182/Blood.V124.21.5906.5906 |
0.325 |
|
| 2014 |
Sloan JM, Sissoko M, Seldin DC, Sworder B, Angelino K, Broce M, Berk JL, Sanchorawala V. Clinical Presentation and Treatment Responses in IgM AL Amyloidosis, a Series of 106 Patients Blood. 124: 4750-4750. DOI: 10.1182/Blood.V124.21.4750.4750 |
0.34 |
|
| 2013 |
Leung A, Nah SK, Reid W, Ebata A, Koch CM, Monti S, Genereux JC, Wiseman RL, Wolozin B, Connors LH, Berk JL, Seldin DC, Mostoslavsky G, Kotton DN, Murphy GJ. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem Cell Reports. 1: 451-63. PMID 24286032 DOI: 10.1016/J.Stemcr.2013.10.003 |
0.333 |
|
| 2013 |
Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, Seldin DC, Lavatelli F, Rognoni P, Palladini G, Merlini G, et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Research in Cardiology. 108: 378. PMID 23982491 DOI: 10.1007/S00395-013-0378-5 |
0.481 |
|
| 2013 |
Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, MacRae CA, Liao R. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. American Journal of Physiology. Heart and Circulatory Physiology. 305: H95-103. PMID 23624626 DOI: 10.1152/Ajpheart.00186.2013 |
0.49 |
|
| 2013 |
Doros G, Quillen K, Sloan JM, Shelton AC, Brauneis D, Finn KT, Seldin DC. Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center Blood. 122: 3328-3328. DOI: 10.1182/Blood.V122.21.3328.3328 |
0.306 |
|
| 2013 |
Sanchorawala V, Seldin DC, Sworder B, Berk JL, Sloan JM. Clinical Presentation and Treatment Responses In IgM-Related AL Amyloidosis Blood. 122: 1991-1991. DOI: 10.1182/Blood.V122.21.1991.1991 |
0.342 |
|
| 2013 |
Seldin DC, Landesman-Bollag E. The Oncogenic Potential of CK2 Protein Kinase Ck2. 292-304. DOI: 10.1002/9781118482490.ch10 |
0.699 |
|
| 2012 |
Imbrie GA, Wu H, Seldin DC, Dominguez I. Asymmetric Localization of CK2α During Xenopus Oogenesis. Human Genetics & Embryology : Current Research. 11328. PMID 25346867 DOI: 10.4172/2161-0436.S4-001 |
0.767 |
|
| 2012 |
Tsai SB, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, Sloan JM, Doros G, Finn KT, Skinner M, Sanchorawala V. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood. 120: 4445-6. PMID 23175664 DOI: 10.1182/Blood-2012-09-457341 |
0.317 |
|
| 2012 |
Shin JT, Ward JE, Collins PA, Dai M, Semigran HL, Semigran MJ, Seldin DC. Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 19: 191-6. PMID 23126591 DOI: 10.3109/13506129.2012.733741 |
0.575 |
|
| 2012 |
Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel P, Seldin ML, Sonenshein GE. Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Research. 72: 6268-78. PMID 23054396 DOI: 10.1158/0008-5472.Can-12-2270 |
0.753 |
|
| 2012 |
Rosenzweig MA, Landau H, Seldin D, O'Hara C, Girnius S, Hanson N, Frosina D, Sedrak C, Arcila M, Comenzo RL, Giralt S, Gnjatic S, Jungbluth AA, Koehne G. Cancer-testis antigen expression and immunogenicity in AL amyloidosis. Blood Cancer Journal. 2: e90. PMID 22983433 DOI: 10.1038/Bcj.2012.32 |
0.309 |
|
| 2012 |
Lee JC, Wu H, Prokaeva TB, O'Hara C, Seldin DC. Expression of D-type cyclins in AL amyloidosis plasma cells. Journal of Clinical Pathology. 65: 1052-5. PMID 22859391 DOI: 10.1136/Jclinpath-2012-200819 |
0.348 |
|
| 2012 |
Shi X, Seldin DC, Garry DJ. Foxk1 recruits the Sds3 complex and represses gene expression in myogenic progenitors. The Biochemical Journal. 446: 349-57. PMID 22716292 DOI: 10.1042/Bj20120563 |
0.39 |
|
| 2012 |
Flies A, Ahmadi T, Parks AJ, Prokaeva T, Weng L, Rolfe SS, Seldin DC, Sherr DH. Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis. Immunology and Cell Biology. 90: 528-39. PMID 21894172 DOI: 10.1038/Icb.2011.73 |
0.329 |
|
| 2012 |
Nair D, Sanchorawala V, Shelton AC, Fennessey SA, Finn KT, Skinner M, Zeldis JB, Seldin DC. Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial Blood. 120: 4084-4084. DOI: 10.1182/Blood.V120.21.4084.4084 |
0.315 |
|
| 2012 |
Sanchorawala V, Shelton AC, Brauneis D, Quillen K, Andrea NT, Sloan JM, Seldin DC. Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation Blood. 120: 2019-2019. DOI: 10.1182/Blood.V120.21.2019.2019 |
0.337 |
|
| 2012 |
Sanchorawala V, Shelton AC, Doros G, Seldin DC. Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide Blood. 120: 1873-1873. DOI: 10.1182/Blood.V120.21.1873.1873 |
0.317 |
|
| 2011 |
Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, Jasuja R, Trinkaus-Randall V, Liao R, Connors LH, Seldin DC. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 118: 6610-7. PMID 21998211 DOI: 10.1182/Blood-2011-04-351643 |
0.642 |
|
| 2011 |
Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica. 96: 1890-2. PMID 21859734 DOI: 10.3324/Haematol.2011.049858 |
0.321 |
|
| 2011 |
Meier-Ewert HK, Sanchorawala V, Berk J, Finn KT, Skinner M, Seldin DC, Ruberg FL. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 18: 125-126. PMID 21838460 DOI: 10.3109/13506129.2011.574354048 |
0.307 |
|
| 2011 |
Ward JE, SooHoo P, Toraldo G, Jasuja R, Connors LH, O'Hara C, Seldin DC. Metabolic phenotype in an AL amyloidosis transgenic mouse model. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 18: 40-1. PMID 21838426 DOI: 10.3109/13506129.2011.574354014 |
0.541 |
|
| 2011 |
Landesman-Bollag E, Belkina A, Hovey B, Connors E, Cox C, Seldin DC. Developmental and growth defects in mice with combined deficiency of CK2 catalytic genes. Molecular and Cellular Biochemistry. 356: 227-31. PMID 21769451 DOI: 10.1007/S11010-011-0967-2 |
0.758 |
|
| 2011 |
Dominguez I, Degano IR, Chea K, Cha J, Toselli P, Seldin DC. CK2α is essential for embryonic morphogenesis. Molecular and Cellular Biochemistry. 356: 209-16. PMID 21761203 DOI: 10.1007/S11010-011-0961-8 |
0.385 |
|
| 2011 |
Hovey BM, Ward JE, Soo Hoo P, O'Hara CJ, Connors LH, Seldin DC. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Therapy. 18: 1150-6. PMID 21562591 DOI: 10.1038/Gt.2011.69 |
0.772 |
|
| 2011 |
Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1924-33. PMID 21483018 DOI: 10.1200/Jco.2010.32.2271 |
0.336 |
|
| 2011 |
Greene MJ, Sam F, Soo Hoo PT, Patel RS, Seldin DC, Connors LH. Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. The American Journal of Pathology. 178: 61-8. PMID 21224044 DOI: 10.1016/J.Ajpath.2010.11.015 |
0.308 |
|
| 2011 |
Quillen K, Seldin DC, Finn KT, Sanchorawala V. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis Bone Marrow Transplantation. 46: 976-980. PMID 20956955 DOI: 10.1038/Bmt.2010.239 |
0.302 |
|
| 2011 |
Girnius S, Seldin DC, Quillen K, Andrea NT, Sloan JM, Berk JL, Ruberg FL, Meier-Ewert H, Sanchorawala V. High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement Blood. 118: 2043-2043. DOI: 10.1182/Blood.V118.21.2043.2043 |
0.306 |
|
| 2011 |
Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Mattar BI, Safah HF, Holmberg L, Dean RM, Orlowski RZ, Barlogie B. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115 Blood. 118: 2004-2004. DOI: 10.1182/Blood.V118.21.2004.2004 |
0.324 |
|
| 2010 |
Sanchorawala V, Seldin DC, Berk JL, Sloan JM, Doros G, Skinner M. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Clinical Lymphoma, Myeloma & Leukemia. 10: 469-72. PMID 21156464 DOI: 10.3816/Clml.2010.N.081 |
0.339 |
|
| 2010 |
Ren R, Hong Z, Gong H, Laporte K, Skinner M, Seldin DC, Costello CE, Connors LH, Trinkaus-Randall V. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. The Journal of Biological Chemistry. 285: 37672-82. PMID 20870723 DOI: 10.1074/Jbc.M110.149575 |
0.306 |
|
| 2010 |
Sanchorawala V, Finn KT, Fennessey S, Shelton A, Doros G, Zeldis JB, Seldin DC. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood. 116: 1990-1. PMID 20847211 DOI: 10.1182/Blood-2010-07-295485 |
0.312 |
|
| 2010 |
Dey BR, Chung SS, Spitzer TR, Zheng H, MacGillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure Transplantation. 90: 905-911. PMID 20733534 DOI: 10.1097/Tp.0B013E3181F10Edb |
0.302 |
|
| 2010 |
Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proceedings of the National Academy of Sciences of the United States of America. 107: 4188-93. PMID 20150510 DOI: 10.1073/Pnas.0912263107 |
0.665 |
|
| 2010 |
Currier N, Chea K, Hlavacova M, Sussman DJ, Seldin DC, Dominguez I. Dynamic expression of a LEF-EGFP Wnt reporter in mouse development and cancer. Genesis (New York, N.Y. : 2000). 48: 183-94. PMID 20146356 DOI: 10.1002/Dvg.20604 |
0.796 |
|
| 2010 |
Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Annals of Hematology. 89: 579-84. PMID 20012043 DOI: 10.1007/S00277-009-0874-8 |
0.322 |
|
| 2010 |
Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction. Bone Marrow Transplantation. 45: 21-4. PMID 19421171 DOI: 10.1038/Bmt.2009.94 |
0.305 |
|
| 2010 |
Cowan AJ, Skinner M, Sloan JM, Berk JL, O'Hara CJ, Seldin DC, Sanchorawala V. Macroglossia – Not Always AL Amyloidosis Blood. 116: 5007-5007. DOI: 10.1182/Blood.V116.21.5007.5007 |
0.323 |
|
| 2010 |
Sanchorawala V, Quillen K, Finn KT, Andrea NT, Sloan JM, Dember L, Segal A, Doros G, Skinner M, Seldin D. High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis Blood. 116: 3553-3553. DOI: 10.1182/Blood.V116.21.3553.3553 |
0.328 |
|
| 2010 |
Sanchorawala V, Finn KT, Fennessey S, Shelton AC, Zeldis JB, Seldin DC. Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis Blood. 116: 3022-3022. DOI: 10.1182/Blood.V116.21.3022.3022 |
0.306 |
|
| 2010 |
Ruberg FL, Sanchorawala V, Berk J, Finn KT, Skinner M, Seldin DC, Meier-Ewert H. Reduction In Ventricular Wall Thickness Following High-Dose Chemotherapy And Stem-Cell Transplantation For Al Cardiac Amyloidosis Journal of the American College of Cardiology. 55. DOI: 10.1016/S0735-1097(10)60352-X |
0.301 |
|
| 2010 |
Sanchorawala V, Yanarella L, Quillen K, Sloan JM, Andrea NT, Finn KT, Seldin DC. Bortezomib And High Dose Melphalan Followed By Autologous Stem Cell Transplantation (B-HDM/SCT) For The Treatment Of Al Amyloidosis: Results Of A Feasibility Study Biology of Blood and Marrow Transplantation. 16. DOI: 10.1016/J.Bbmt.2009.12.157 |
0.301 |
|
| 2009 |
Wu H, Symes K, Seldin DC, Dominguez I. Threonine 393 of beta-catenin regulates interaction with Axin. Journal of Cellular Biochemistry. 108: 52-63. PMID 19565571 DOI: 10.1002/Jcb.22260 |
0.343 |
|
| 2009 |
Dominguez I, Sonenshein GE, Seldin DC. CK2 and its role in Wnt and NF-κB signaling: Linking development and cancer Cellular and Molecular Life Sciences. 66: 1850-1857. PMID 19387549 DOI: 10.1007/S00018-009-9153-Z |
0.427 |
|
| 2009 |
Charlot M, Seldin DC, O'Hara C, Skinner M, Sanchorawala V. Localized AL Amyloidosis of the Breast: A Case Series. Blood. 114: 4906-4906. DOI: 10.1182/Blood.V114.22.4906.4906 |
0.337 |
|
| 2009 |
Girnius S, Seldin DC, Quillen K, Finn KT, Andrea NT, Sloan JM, Sanchorawala V. Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders. Blood. 114: 4356-4356. DOI: 10.1182/Blood.V114.22.4356.4356 |
0.319 |
|
| 2009 |
Sanchorawala V, Yanarella L, Quillen K, Sloan JM, Andrea NT, Finn KT, Seldin DC. Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study. Blood. 114: 4353-4353. DOI: 10.1182/Blood.V114.22.4353.4353 |
0.352 |
|
| 2009 |
Quillen K, Seldin DC, Finn KT, Sanchorawala V. Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis. Blood. 114: 2318-2318. DOI: 10.1182/Blood.V114.22.2318.2318 |
0.304 |
|
| 2009 |
Sanchorawala V, Seldin DC, Sloan JM, Berk JL, Skinner M. Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation. Blood. 114: 1883-1883. DOI: 10.1182/Blood.V114.22.1883.1883 |
0.336 |
|
| 2008 |
Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, Bharti A, Seldin DC, Lecker SH, Dominguez I, Cohen HT. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nature Cell Biology. 10: 1208-16. PMID 18806787 DOI: 10.1038/Ncb1781 |
0.343 |
|
| 2008 |
Seldin DC, Lou DY, Toselli P, Landesman-Bollag E, Dominguez I. Gene targeting of CK2 catalytic subunits. Molecular and Cellular Biochemistry. 316: 141-7. PMID 18594950 DOI: 10.1007/S11010-008-9811-8 |
0.795 |
|
| 2008 |
Lavatelli F, Perlman DH, Spencer B, Prokaeva T, McComb ME, Théberge R, Connors LH, Bellotti V, Seldin DC, Merlini G, Skinner M, Costello CE. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Molecular & Cellular Proteomics : McP. 7: 1570-83. PMID 18474516 DOI: 10.1074/Mcp.M700545-Mcp200 |
0.311 |
|
| 2008 |
Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O'Brien C, Seldin DC. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Molecular and Cellular Biology. 28: 131-9. PMID 17954558 DOI: 10.1128/Mcb.01119-07 |
0.804 |
|
| 2008 |
Sanchorawala V, Skinner M, Finn KT, Quillen K, Seldin DC. Treatment-Related Mortality in Patients with AL Amyloidosis Undergoing High-Dose Melphalan and Stem Cell Transplantation: Trend Over the Past 14 Years at a Single Institution Blood. 112: 53-53. DOI: 10.1182/Blood.V112.11.53.53 |
0.316 |
|
| 2008 |
Hovey BM, Ward J, Seldin DC. siRNA, a Potential Therapy for AL Amyloidosis. Blood. 112: 1714-1714. DOI: 10.1182/Blood.V112.11.1714.1714 |
0.78 |
|
| 2008 |
Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile Reactions Occurring with Second Cycle of High Dose Melphalan and Stem Cell Transplantation in Patients with AL Amyloidosis: A “Melphalan Recall” Reaction. Blood. 112: 1120-1120. DOI: 10.1182/Blood.V112.11.1120.1120 |
0.331 |
|
| 2008 |
Seldin DC, Ward JE. Serum Free Light Chain Analysis, 4th Edition Amyloid. 15: 142-143. DOI: 10.1080/13506120802006344 |
0.49 |
|
| 2007 |
Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, Sherr DH, Sonenshein GE. Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Research. 67: 11742-50. PMID 18089804 DOI: 10.1158/0008-5472.Can-07-2730 |
0.38 |
|
| 2007 |
Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 14: 261-9. PMID 17968685 DOI: 10.1080/13506120701613984 |
0.311 |
|
| 2007 |
Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 110: 3561-3. PMID 17673601 DOI: 10.1182/Blood-2007-07-099481 |
0.302 |
|
| 2007 |
Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis Bone Marrow Transplantation. 40: 557-562. PMID 17589534 DOI: 10.1038/Sj.Bmt.1705746 |
0.318 |
|
| 2007 |
Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O'Hara C, Connors L, Skinner M, Seldin DC. Association of acquired von Willebrand syndrome with AL amyloidosis. American Journal of Hematology. 82: 363-7. PMID 17205535 DOI: 10.1002/Ajh.20829 |
0.567 |
|
| 2007 |
Dey BR, Spitzer TR, MacGillivray TE, Chung SS, Dec GW, Seldin DC, McAfee SL, Ballen K, Attar E, Skinner M, Madsen JC, Semigran MJ. Cardiac Transplant Followed by High-Dose Melphalan and Autologous Stem Cell Transplantation (ASCT) for Patients with AL Amyloidosis and Severe Heart Failure. Blood. 110: 732-732. DOI: 10.1182/Blood.V110.11.732.732 |
0.306 |
|
| 2007 |
Girnius S, Seldin DC, Skinner M, Finn KT, Sanchorawala V. Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease. Blood. 110: 2873-2873. DOI: 10.1182/Blood.V110.11.2873.2873 |
0.315 |
|
| 2007 |
Seldin DC, Rosenzweig M, Finn KT, Fennessey S, Shelton A, Zeldis JB, Skinner M, Sanchorawala V. Durable Responses to Lenalidomide (Revlimid®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial. Blood. 110: 192-192. DOI: 10.1182/Blood.V110.11.192.192 |
0.311 |
|
| 2006 |
Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, Sherr DH. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biological Chemistry. 387: 1175-87. PMID 16972784 DOI: 10.1515/Bc.2006.145 |
0.614 |
|
| 2006 |
Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood. 108: 3945-7. PMID 16926284 DOI: 10.1182/Blood-2006-06-029728 |
0.309 |
|
| 2006 |
Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, Skinner M, Seldin DC, Sanchorawala V. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplantation. 38: 339-43. PMID 16862166 DOI: 10.1038/Sj.Bmt.1705447 |
0.31 |
|
| 2006 |
Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. The Journal of Clinical Investigation. 116: 1913-23. PMID 16823489 DOI: 10.1172/Jci27933 |
0.308 |
|
| 2006 |
Sanchorawala V, Blanchard E, Seldin DC, O'Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: Frequency and treatment outcomes American Journal of Hematology. 81: 692-695. PMID 16795060 DOI: 10.1002/Ajh.20635 |
0.332 |
|
| 2006 |
Sanchorawala V, Wright DG, Quillen K, Dember LM, Berk JL, Finn KT, Skinner M, Seldin DC. Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial. Blood. 108: 612-612. DOI: 10.1182/Blood.V108.11.612.612 |
0.339 |
|
| 2006 |
Seldin DC, Skinner M, Oran B, Quillen K, Finn KT, Sanchorawala V. Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT). Blood. 108: 3094-3094. DOI: 10.1182/Blood.V108.11.3094.3094 |
0.308 |
|
| 2005 |
Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Research. 65: 11375-83. PMID 16357145 DOI: 10.1158/0008-5472.Can-05-1602 |
0.762 |
|
| 2005 |
Dominguez I, Mizuno J, Wu H, Imbrie GA, Symes K, Seldin DC. A role for CK2alpha/beta in Xenopus early embryonic development. Molecular and Cellular Biochemistry. 274: 125-31. PMID 16342412 DOI: 10.1007/S11010-005-3073-5 |
0.78 |
|
| 2005 |
Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I. CK2 as a positive regulator of Wnt signalling and tumourigenesis. Molecular and Cellular Biochemistry. 274: 63-7. PMID 16342409 DOI: 10.1007/S11010-005-3078-0 |
0.782 |
|
| 2005 |
Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H, Dominguez I, Sonenshein GE, Cardiff RD, Xiao ZX, Sherr DH, Seldin DC. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicologic Pathology. 33: 726-37. PMID 16263698 DOI: 10.1080/01926230500352226 |
0.795 |
|
| 2005 |
Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang X, Shin SR, Landesman-Bollag E, Seldin DC, Sonenshein GE. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Molecular and Cellular Biology. 25: 10136-47. PMID 16260626 DOI: 10.1128/Mcb.25.22.10136-10147.2005 |
0.743 |
|
| 2005 |
Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis Bone Marrow Transplantation. 36: 597-600. PMID 16044137 DOI: 10.1182/Blood.V104.11.942.942 |
0.324 |
|
| 2005 |
Farago M, Dominguez I, Landesman-Bollag E, Xu X, Rosner A, Cardiff RD, Seldin DC. Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Research. 65: 5792-801. PMID 15994955 DOI: 10.1158/0008-5472.Can-05-1021 |
0.816 |
|
| 2005 |
Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis Bone Marrow Transplantation. 35: 567-575. PMID 15665842 DOI: 10.1038/Sj.Bmt.1704826 |
0.307 |
|
| 2005 |
Weichman KI, Seldin DC, Quillen K, Rosenzweig M, Dember LM, Skinner M, Wright DG, Sanchorawala V. High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders. Blood. 106: 5476-5476. DOI: 10.1182/Blood.V106.11.5476.5476 |
0.317 |
|
| 2005 |
Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O’Hara C, Connors L, Skinner M, Seldin DC. Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis. Blood. 106: 4078-4078. DOI: 10.1182/Blood.V106.11.4078.4078 |
0.572 |
|
| 2005 |
Ward JE, Brenner D, Cui L, Liao R, Connors LH, Hoo PS, Eberhard J, Christensen T, O’Hara C, Skinner M, Seldin DC. Expression of Human Amyloidogenic Immunoglobulin Light Chains in Mice Leads to Organ Toxicity. Blood. 106: 3412-3412. DOI: 10.1182/Blood.V106.11.3412.3412 |
0.597 |
|
| 2004 |
Sipe JD, Seldin DC. Xth International Symposium on Amyloid and Amyloidosis April 18-22, 2004 (selected highlights) Tours, Loire Valley, France. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 11: 268-72. PMID 15678763 DOI: 10.1080/13506120400016257 |
0.312 |
|
| 2004 |
Dominguez I, Mizuno J, Wu H, Song DH, Symes K, Seldin DC. Protein kinase CK2 is required for dorsal axis formation in Xenopus embryos. Developmental Biology. 274: 110-24. PMID 15355792 DOI: 10.1016/J.Ydbio.2004.06.021 |
0.608 |
|
| 2004 |
Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine. 140: 85-93. PMID 14734330 DOI: 10.7326/0003-4819-140-2-200401200-00008 |
0.332 |
|
| 2004 |
Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: Results of a prospective randomized trial Bone Marrow Transplantation. 33: 381-388. PMID 14676787 DOI: 10.1038/Sj.Bmt.1704346 |
0.314 |
|
| 2004 |
Quillen K, Wright DG, Seldin DC, Skinner M, Malek K, Finn KT, Sanchorawala V. Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis. Blood. 104: 5226-5226. DOI: 10.1182/Blood.V104.11.5226.5226 |
0.314 |
|
| 2004 |
Sanchorawala V, Seldin DC, Wright DG, Skinner M, Finn KT, Falk RH. Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation. Blood. 104: 2393-2393. DOI: 10.1182/Blood.V104.11.2393.2393 |
0.336 |
|
| 2003 |
Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis American Journal of Hematology. 74: 131-135. PMID 14508801 DOI: 10.1002/Ajh.10389 |
0.327 |
|
| 2003 |
Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Molecular and Cellular Biology. 23: 5738-54. PMID 12897145 DOI: 10.1128/Mcb.23.16.5738-5754.2003 |
0.756 |
|
| 2003 |
Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC. CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. The Journal of Biological Chemistry. 278: 24018-25. PMID 12700239 DOI: 10.1074/Jbc.M212260200 |
0.616 |
|
| 2003 |
Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH, O'Hara C, Fennessey S, Finn KT, Wright DG, Skinner M, Sanchorawala V. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clinical Lymphoma. 3: 241-6. PMID 12672274 DOI: 10.3816/Clm.2003.N.005 |
0.34 |
|
| 2003 |
Ramirez MI, Millien G, Hinds A, Cao Y, Seldin DC, Williams MC. T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Developmental Biology. 256: 61-72. PMID 12654292 DOI: 10.1016/S0012-1606(02)00098-2 |
0.324 |
|
| 2003 |
Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney International. 63: 1051-7. PMID 12631087 DOI: 10.1046/J.1523-1755.2003.00813.X |
0.325 |
|
| 2002 |
Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Research. 62: 6770-8. PMID 12438279 |
0.747 |
|
| 2002 |
Miller SJ, Lou DY, Seldin DC, Lane WS, Neel BG. Direct identification of PTEN phosphorylation sites Febs Letters. 528: 145-153. PMID 12297295 DOI: 10.1016/S0014-5793(02)03274-X |
0.754 |
|
| 2002 |
Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, Cardiff RD. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. The American Journal of Pathology. 161: 1087-97. PMID 12213737 DOI: 10.1016/S0002-9440(10)64269-1 |
0.748 |
|
| 2002 |
Miyoshi K, Rosner A, Nozawa M, Byrd C, Morgan F, Landesman-Bollag E, Xu X, Seldin DC, Schmidt EV, Taketo MM, Robinson GW, Cardiff RD, Hennighausen L. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene. 21: 5548-56. PMID 12165853 DOI: 10.1038/Sj.Onc.1205686 |
0.755 |
|
| 2002 |
Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene. 21: 5280-8. PMID 12149649 DOI: 10.1038/Sj.Onc.1205640 |
0.799 |
|
| 2001 |
Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE, Seldin DC. Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Molecular and Cellular Biochemistry. 227: 153-65. PMID 11827167 DOI: 10.1023/A:1013108822847 |
0.804 |
|
| 2001 |
Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis Bone Marrow Transplantation. 28: 637-642. PMID 11704785 DOI: 10.1038/Sj.Bmt.1703200 |
0.349 |
|
| 2001 |
Shen J, Channavajhala P, Seldin DC, Sonenshein GE. Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBalpha. Journal of Immunology (Baltimore, Md. : 1950). 167: 4919-25. PMID 11673497 DOI: 10.4049/Jimmunol.167.9.4919 |
0.793 |
|
| 2001 |
Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene. 20: 3247-57. PMID 11423974 DOI: 10.1038/Sj.Onc.1204411 |
0.815 |
|
| 2001 |
Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease Annals of Internal Medicine. 134: 746-753. PMID 11329232 DOI: 10.7326/0003-4819-134-9_Part_1-200105010-00011 |
0.314 |
|
| 2001 |
Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Research. 61: 3810-8. PMID 11325857 |
0.754 |
|
| 2000 |
Song DH, Sussman DJ, Seldin DC. Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. The Journal of Biological Chemistry. 275: 23790-7. PMID 10806215 DOI: 10.1074/Jbc.M909107199 |
0.638 |
|
| 2000 |
Ford HL, Landesman-Bollag E, Dacwag CS, Stukenberg PT, Pardee AB, Seldin DC. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. The Journal of Biological Chemistry. 275: 22245-54. PMID 10801845 DOI: 10.1074/Jbc.M002446200 |
0.76 |
|
| 1999 |
Xu X, Toselli PA, Russell LD, Seldin DC. Globozoospermia in mice lacking the casein kinase ii α catalytic subunit Nature Genetics. 23: 118-121. PMID 10471512 DOI: 10.1038/12729 |
0.419 |
|
| 1999 |
Xu X, Landesman-Bollag E, Channavajhala PL, Seldin DC. Murine protein kinase CK2: gene and oncogene. Molecular and Cellular Biochemistry. 191: 65-74. PMID 10094394 DOI: 10.1007/978-1-4419-8624-5_9 |
0.802 |
|
| 1998 |
Rifkin IR, Channavajhala PL, Kiefer HL, Carmack AJ, Landesman-Bollag E, Beaudette BC, Jersky B, Salant DJ, Ju ST, Marshak-Rothstein A, Seldin DC. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha. Journal of Immunology (Baltimore, Md. : 1950). 161: 5164-70. PMID 9820486 |
0.786 |
|
| 1998 |
Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC. p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene. 16: 2965-74. PMID 9662328 DOI: 10.1038/Sj.Onc.1201854 |
0.793 |
|
| 1998 |
Xu X, Rich ES, Seldin DC. Murine protein kinase CK2 alpha': cDNA and genomic cloning and chromosomal mapping. Genomics. 48: 79-86. PMID 9503019 DOI: 10.1006/Geno.1997.5154 |
0.324 |
|
| 1996 |
Kelliher MA, Seldin DC, Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. The Embo Journal. 15: 5160-6. PMID 8895560 DOI: 10.1002/J.1460-2075.1996.Tb00900.X |
0.377 |
|
| 1995 |
Seldin DC. New models of lymphoma in transgenic mice Current Opinion in Immunology. 7: 665-673. PMID 8573310 DOI: 10.1016/0952-7915(95)80075-1 |
0.309 |
|
| 1995 |
Seldin DC, Leder P. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science (New York, N.Y.). 267: 894-7. PMID 7846532 DOI: 10.1126/Science.7846532 |
0.386 |
|
| 1993 |
Skoda RC, Seldin DC, Chiang MK, Peichel CL, Vogt TF, Leder P. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. The Embo Journal. 12: 2645-53. PMID 8334987 DOI: 10.1002/J.1460-2075.1993.Tb05925.X |
0.312 |
|
| Show low-probability matches. |